Intellipharmaceutics International Inc.
(Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a
pharmaceutical company specializing in the research, development
and manufacture of novel and generic controlled-release and
targeted-release oral solid dosage drugs, today announced that the
Company is scheduled to present at the Dawson James Securities
Growth Stock Conference on October 15, 2015. The presentation will
take place at 11:45 A.M. (EDT) in the Wyndham Grand Hotel in
Jupiter, Florida.
The presentation may be accessed through the Investor Relations'
Events and Presentations section on Intellipharmaceutics' website
at www.intellipharmaceutics.com.
About Intellipharmaceutics
Intellipharmaceutics International Inc. is a pharmaceutical
company specializing in the research, development and manufacture
of novel and generic controlled-release and targeted-release oral
solid dosage drugs. The Company's patented Hypermatrix™ technology
is a multidimensional controlled-release drug delivery platform
that can be applied to the efficient development of a wide range of
existing and new pharmaceuticals. Based on this technology
platform, Intellipharmaceutics has developed several drug delivery
systems and a pipeline of products (our dexmethylphenidate
hydrochloride extended-release capsules for the 15 and 30 mg
strengths which received final United States Food and Drug
Administration ("FDA") approval) and product candidates in various
stages of development, including Abbreviated New Drug Applications
("ANDAs ") filed with the FDA (and one Abbreviated New Drug
Submissions ("ANDSs") filed with Health Canada) in therapeutic
areas that include neurology, cardiovascular, gastrointestinal
tract, diabetes and pain.
Intellipharmaceutics also has New Drug Application ("NDA")
505(b)(2) specialty drug product candidates in its development
pipeline. These include Rexista™ Oxycodone XR, an abuse deterrent
oxycodone based on its proprietary nPODDDS™ novel Point Of
Divergence Drug Delivery System and PODRAS™ Paradoxical OverDose
Resistance Activating System, and Regabatin™ XR pregabalin
extended-release capsules. Our current development effort is
increasingly directed towards improved difficult-to-develop
controlled-release drugs which follow an NDA 505(b)(2) regulatory
pathway. The Company has increased its research and development
emphasis towards new product development, facilitated by the
505(b)(2) regulatory pathway, by advancing the product development
program for both Rexista™ and Regabatin™. The 505(b)(2)
pathway (which relies in part upon the approving agency's findings
for a previously approved drug) both accelerates development
timelines and reduces costs in comparison to NDAs for new chemical
entities. An advantage of our strategy for development of NDA
505(b)(2) drugs is that our product candidates can, if approved for
sale by the FDA, potentially enjoy an exclusivity period which may
provide for greater commercial opportunity relative to the generic
ANDA route.
Certain statements in this document and the upcoming
presentation constitute "forward-looking statements" within the
meaning of the United States Private Securities Litigation Reform
Act of 1995 and/or "forward-looking information" under the
Securities Act (Ontario). These statements include, without
limitation, statements expressed or implied regarding our plans,
goals and milestones, status of developments or expenditures
relating to our business, plans to fund our current activities,
statements concerning our partnering activities, health regulatory
submissions, strategy, future operations, future financial
position, future sales, revenues and profitability, projected
costs, and market penetration. In some cases, you can identify
forward-looking statements by terminology such as "may," "will,"
"should," "expects," "plans," "plans to," "anticipates,"
"believes," "estimates," "predicts," "potential," "continue,"
"intends," "could," or the negative of such terms or other
comparable terminology. We made a number of assumptions in the
preparation of our forward-looking statements. You should not place
undue reliance on our forward-looking statements, which are subject
to a multitude of known and unknown risks and uncertainties that
could cause actual results, future circumstances or events to
differ materially from those stated in or implied by the
forward-looking statements. Risks, uncertainties and other factors
that could affect our actual results include, but are not limited
to, the effects of general economic conditions, securing and
maintaining corporate alliances, our estimates regarding our
capital requirements, and the effect of capital market conditions
and other factors, including the current status of our product
development programs, on capital availability, the potential
dilutive effects of any future financing and the expected use of
any proceeds from any offering of our securities, our ability to
maintain compliance with the continued listing requirements of the
principal markets on which our securities are traded, our programs
regarding research, development and commercialization of our
product candidates, the timing of such programs, the timing, costs
and uncertainties regarding obtaining regulatory approvals to
market our product candidates and the difficulty of predicting the
timing and results of any product launches, and the timing and
amount of any available investment tax credits, the actual or
perceived benefits to users of our drug delivery technologies,
products and product candidates as compared to others, our ability
to establish and maintain valid and enforceable intellectual
property rights in our drug delivery technologies, products and
product candidates, the scope of protection provided by
intellectual property for our drug delivery technologies, products
and product candidates, the actual size of the potential markets
for any of our products and product candidates compared to our
market estimates, our selection and licensing of products and
product candidates, our ability to attract distributors and
collaborators with the ability to fund patent litigation and with
acceptable development, regulatory and commercialization expertise
and the benefits to be derived from such collaborative efforts,
sources of revenues and anticipated revenues, including
contributions from distributors and collaborators, product sales,
license agreements and other collaborative efforts for the
development and commercialization of product candidates, our
ability to create an effective direct sales and marketing
infrastructure for products we elect to market and sell directly,
the rate and degree of market acceptance of our products, delays
that may be caused by changing regulatory requirements, the
difficulty in predicting the timing of regulatory approval and the
timing of launch of competitive products, the difficulty of
predicting the impact of competitive products on volume and
pricing, the inability to forecast wholesaler demand and/or
wholesaler buying patterns, the seasonal fluctuation in the numbers
of prescriptions written for our dexmethylphenidate hydrochloride
extended-release capsules which may produce substantial
fluctuations in revenues, the timing and amount of insurance
reimbursement for our products, changes in the laws and
regulations, including Medicare and Medicaid, affecting among other
things, pricing and reimbursement of pharmaceutical products, the
success and pricing of other competing therapies that may become
available, our ability to retain and hire qualified employees, the
availability and pricing of third party sourced products and
materials, difficulties or delays in manufacturing, the
manufacturing capacity of third-party manufacturers that we may use
for our products, the successful compliance with FDA, Health Canada
and other governmental regulations applicable to the Company and
its third party manufacturers' facilities, products and/or
businesses, difficulties, delays or changes in the FDA approval
process or test criteria for ANDAs and NDAs and risks associated
with cyber-security and vulnerability of the Company's digital
information and the digital information of the Company's
commercialization partner(s). Additional risks and uncertainties
relating to the Company and our business can be found in the "Risk
Factors" section of our latest annual information form, our latest
Form 20-F, and our latest Form F-3 (including any documents forming
a part thereof or incorporated by reference therein), as well as in
our reports, public disclosure documents and other filings with the
securities commissions and other regulatory bodies in Canada and
the U.S., which are available on www.sedar.com and www.sec.gov. The
forward-looking statements reflect our current views with respect
to future events and are based on what we believe are reasonable
assumptions as of the date of this document, and we disclaim any
intention and have no obligation or responsibility, except as
required by law, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
CONTACT: Company Contact:
Intellipharmaceutics International Inc.
Domenic Della Penna
Chief Financial Officer
416-798-3001 ext 106
investors@intellipharmaceutics.com
Investor Contact:
ProActive Capital
Kirin Smith
646-863-6519
ksmith@proactivecapital.com
IntelliPharmaCeutics (QB) (USOTC:IPCIF)
Historical Stock Chart
From Feb 2024 to Mar 2024
IntelliPharmaCeutics (QB) (USOTC:IPCIF)
Historical Stock Chart
From Mar 2023 to Mar 2024